A close relationship between Helicobacter pylori infection and the serum level of CD47 in adults. (2nd June 2020)

• Record Type: Journal Article
• Authors: Feng, Lei; Jian, Rong; Wang, Yan; Yao, Yong; Gao, Mingsheng; Du, Heng
• Is Part Of: Scandinavian journal of gastroenterology. Volume 55:Number 6(2020)
• Page Start: 640
• Page End: 645
• Publication Date: 2020-06-02
• Subjects: Helicobacter pylori -- TNF-α -- integrin-associated protein -- CD47 -- relationship -- serum -- gastric cancer; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2020.1772863
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Objectives: Although Helicobacter pylori ( H . pylori ) infection is one of the most important risk factors for gastric cancer, the molecular mechanisms underlying the progression of H . pylori -induced gastric cancer remain unclear. Previous studies have demonstrated that Integrin-associated protein (CD47) plays an important role in the development of gastric cancer. Hence, the aim of this study was to preliminarily explore the relationship between CD47 and H. pylori infection. Methods: A total of 417 adults who underwent health checkups at a hospital were recruited in 2018. Serum levels of CD47 and tumor necrosis factor-α (TNF-α) were determined using an enzyme-linked immunosorbent assay. 13 C urea breath test ( 13 C-UBT) was carried out to diagnose H . pylori infection in all participants. Results: Compared with H. pylori -negative participants, H. pylori -positive participants have higher levels of serum CD47 and TNF-α. H. pylori infection, the levels of serum TNF-α and low density lipoprotein (LDL) are the independent predictors of serum level of CD47 in adults. In addition, a potential diagnostic value of serum CD47 level for H. pylori infection has been demonstrated in our study. Conclusion: H. pylori infection is closely associated with the serum level of CD47 in adults, suggesting that H . pylori may promote gastric cancer progression by activating CD47-mediated oncogenic pathways.